BMS said it will launch Cobenfy within the next few weeks and has set a price of $1,850 per month for the medicine, which is considerably more than the current, largely generic array of ...

The decision to go all-in on the programme comes two years after BMS paid $80 million to take exclusive, worldwide opt-in rights to PRX005, and means that the big pharma will now be responsible ...